Trial Profile
Phase I Study (First in Humans) of the Amblyomin-X in the Treatment of Patients With Advanced Solid Tumors Refractory or Without Indication / Access to Standard Treatment
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 16 Oct 2019
Price :
$35
*
At a glance
- Drugs Amblyomin-X (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 11 Oct 2019 Planned End Date changed from 30 Jun 2018 to 22 May 2022.
- 11 Oct 2019 Planned primary completion date changed from 30 Jan 2018 to 20 Aug 2021.
- 11 Oct 2019 Planned initiation date changed from 30 Nov 2017 to 15 Feb 2021.